The Lambert-Eaton Myasthenic Syndrome

Authors: Antoine F Carpentier; Jean-Yves Delattre

Source: Clinical Reviews in Allergy and Immunology, Volume 20, Number 1, February 2001 , pp. 155-158(4)

Publisher: Humana Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

The Lambert-Eaton Myasthenic Syndrome (LEMS) is a disorder of neuromuscular transmission, characterized by reduced release of acetylcholine from the motor nerve terminal (1). LEMS is suspected to be an autoimmune disease. This was first suggested by the association of LEMS with other autoimmune diseases (2) and the clinical response to plasma exchange and immunosuppressive therapy (3,4). Direct evidence of the autoimmune mechanism has been provided by passive transfer experiment in which electrophysiological features of LEMS can be induced in animals after injection of purified IgG from patients with LEMS (5,6). Antibodies against presynaptic voltage-gated calcium channels (VGCC) are believed to play an important role in the pathogenesis of LEMS by inhibiting the calcium currents that trigger acetylcholine release.

Keywords: Lambert-Eaton Myasthenic Syndrome, Small-Cell Lung

Document Type: Miscellaneous

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$42.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A